December 2, 2021
Life Sciences
  • A federal appeals court on Wednesday dismissed two patent challenges from Moderna over key components involved in making its COVID-19 vaccine. The court’s decision to side with Canadian biopharmaceutical company ​​Arbutus Biopharma Corporation means Arbutus could potentially sue Moderna for patent infringement and demand royalties from Moderna’s COVID-19 vaccine, which is expected to generate up to $18 billion of revenue this year. (Articles here and here)